#CareerAdvice: Three executives whose combined careers include working at companies including Amgen, AstraZeneca, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer and Takeda share their career journeys with BioSpace. Not everyone stays at large #biopharma companies for their entire careers. Some move into smaller organizations. Their reasons vary. An opportunity too good to pass up comes along. They want to do specialized work that could help a loved one. Their career path naturally leads them into a smaller organization. Whatever the reason, these biopharma professionals end up at companies that differ in ways both challenging and rewarding from the ones they left behind. Below, three executives with dozens of combined years of experience at companies including Amgen, AstraZeneca, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer and Takeda share their journeys of moving from large to small biopharmas—and offer advice for those making or considering similar moves. Read their stories below at BioSpace 👇🏼 https://lnkd.in/e6c9VmyY
Rizwan Chaudhrey’s Post
More Relevant Posts
-
Once again in March, the #pharmaceutical world saw a series of notable #hires. From #biotech to #pharma, companies are strengthening their teams with experienced professionals. Here’s a round-up of the key appointments. #ChangingFaces https://lnkd.in/eVhwZy-6
Changing Faces: Pharma and biotech hires from March 2024
pharmaphorum.com
To view or add a comment, sign in
-
😎 Hello, #biopharma #hubspots and those interested in #mergersandacquisitions! Here's some #news you can use according to BioSpace: Today’s #financial landscape and #market conditions are creating a #buyers’ market in #biopharma. These transactions reflect an appetite to fill #product #development #pipelines and increase #revenues, particularly in #obesity, #oncology, and #immunology. 💸 Last week, the sale of listed contract drugmaker Catalent Pharma Solutions to Novo Nordisk follows Johnson & Johnson’s agreement to acquire Ambrx Biopharma for $2B, Gilead Sciences’ $4.3B acquisition of CymaBay Therapeutics, Bristol Myers Squibb’ $4B acquisition of RayzeBio, and Pfizer’s $43B acquisition of Seagen. Since #valuations have diminished for many companies with little cash but good assets, #bigpharma buyers and certain mid-size regional players are in an excellent position to #negotiate the best deals. Smaller companies developing differentiated #products generating strong #revenue and showing #growthopportunity are highly attractive to large #lifescience companies. A higher price is worth not bringing a potential product from #concept to #clinic. Late-stage products attract #buyers because the #developers absorb much of the #regulatory and #clinical risk.
Opinion: 2024 Will Be a Buyers’ Market in Biopharma. It Already Is. | BioSpace
biospace.com
To view or add a comment, sign in
-
Shareable Insights by Citeline | Week 28/2024, Part 1 Scrip: Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition https://lnkd.in/dcbeExma •Who should read this? #pharma and #biotech executives in R&D, BD&L, competitor intelligence; pharma consultants at professional services firms. •What is it? News that Pfizer’s R&D leader Mikael Dolsten is to leave the company after 15 years. •Why is it important? Major leadership changes at big pharma are often followed by a change in strategic focus. With Pfizer facing the challenge of generating growth from its pipeline following the huge rise and rapid decline in its revenues from COVID-19 products, and as one of the world’s biggest pharma companies, this development will likely have significant repercussions for the wider biopharma ecosystem. It may impact Pfizer’s current and future partnerships and its competitive position in the market. Furthermore, there is the prospect of another industry R&D leader taking on the vacant role.
Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition
scrip.citeline.com
To view or add a comment, sign in
-
See the link in the post below for a short summary of our webinar on early market access for biotech and investors #marketaccess #pharma #biotech
Why does market access play such a critical role in drug development? In our recent discussion with FINGERPOST, industry experts share their perspectives on the importance of market access and health economics and outcomes research (HEOR) in early commercial decision-making for biotech and large pharmaceutical companies. Read the blog recap today: https://lnkd.in/gXXzRY7j Mel Walker, Joep Muijrers, Sandeep Duttagupta, Sahil Kirpekar, MD, Hilary Hutton-Squire
From Development to Delivery: Prioritizing Market Access in Biotech and Pharma
app.scientist.com
To view or add a comment, sign in
-
💰 July's Key Buyout Deals in Healthcare & Life Sciences in Europe 🧬 🇮🇹 Italy: Ardian has acquired a majority stake in MASCO GROUP, a company that manufactures components for the medical and pharmaceutical industries. 🇬🇷 Greece: MidEuropa has acquired a majority stake in FAMAR, a leading contract manufacturing organization in the pharmaceutical industry. 🇨🇭 Switzerland: CordenPharma has announced an investment to grow its peptide technology platform, enhancing its capabilities in the production of complex peptides for pharmaceutical use. 🇩🇰 Denmark: Duke Street is set to acquire Agito Medical from Philips. Agito Medical provides mobile imaging equipment for hospitals and clinics. 🇬🇧 UK: Exponent has made an investment in Kingsbridge Healthcare Group, a company providing a range of healthcare services, including private hospitals and clinics. 🇪🇸 Spain: Grifols considering going private, focusing on its global expansion and new product developments in the biopharmaceutical sector. 🇬🇧 UK: Myricx Bio has raised $90 million in Series A financing to advance its NMTi ADC therapeutics into clinical development, targeting cancer treatments. Source : Investors in Healthcare 👍 If you found this insightful, don’t forget to like and share! ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. 👇 For more content like this Join 14K+ followers by clicking my name + follow 🔔 Join 1.3K+ subscribers to my newsletter 💌
To view or add a comment, sign in
-
🚀 Who Will the Next “Big Pharma” Players Be? 🚀 🔬 Insights from Nadia Bey's BioSpace article, Biopharma industry experts, take note: 1️⃣ Top Pharma Revenue: Johnson & Johnson led 2023 with over $85B in sales. AstraZeneca targets $80B by 2030, having made nearly $46B last year. 2️⃣ Growing Contenders: Regeneron, Vertex Pharmaceuticals, BioNTech SE, and Moderna are pushing into Big Pharma territory, with many surpassing $10B in annual revenue and joining GlobalData's top 20 by market cap. 3️⃣ Market Cap Milestones: Gilead Sciences, Regeneron, and Vertex Pharmaceuticals each boast market caps nearing or exceeding $100B, competing with GSK, Bristol Myers Squibb, and not far behind Amgen, Sanofi, and Pfizer. 4️⃣ Geographic Reach: Established players like Pfizer and J&J operate in 150+ and 175+ countries, respectively. Pharma expansion strategies vary, with biotech firms often concentrating in wealthier markets. 5️⃣ Strategic Acquisitions: Vertex acquired Alpine for $4.9B in April 2024, highlighting the ongoing trend of growth through acquisitions. 6️⃣ Revenue Surges: BioNTech, Regeneron, and Moderna saw significant revenue spikes in 2021 due to COVID-19 contributions, with Regeneron maintaining over $10B through 2023. 7️⃣ R&D Focus: Vertex's revenue hit nearly $10B in 2023, with a 13% YoY increase in Q1 2024. The company is expanding beyond cystic fibrosis to address acute and neuropathic pain. 8️⃣ Innovative Tech: Moderna is revolutionizing with mRNA and LNP technology, reminiscent of Regeneron's antibody innovations in the late '90s. 9️⃣ Stock Movements: Moderna and BioNTech's stocks rose in late May 2024 amid H5N1 concerns, indicating their continued relevance and investor interest in mRNA. 🔟 Expanding Influence: Gilead surpassed $10B revenue in 2013, doubling it by 2014. The firm’s global footprint spans 35 countries, with ongoing portfolio expansion. Stay updated as these rising stars challenge the incumbents, shaping the future of our industry. 🌍💉 #Biopharma #BigPharma #IndustryInsights #BiotechInnovations #RevenueGrowth #GlobalMarket #StrategicGrowth
Who Will the Next “Big Pharma” Players Be? | BioSpace
biospace.com
To view or add a comment, sign in
-
Job Alert:- Have you decided that biopharmaceutical consulting is for you? Are you looking to become the catalyst between clinical and commercial success? Prescient is looking for post-graduates and early-career consultants to join us as Associates for our growing Intelligence & Insight business in India. If so, consider turning your expertise into a valuable career at Prescient. hashtag #AssociateConsultant #oncology #lifesciences #hiring #CompetitiveIntelligence
Associate Consultant, Intelligence & Insight - Gurgaon - Prescient Healthcare Group - 4 to 7 years of experience
naukri.com
To view or add a comment, sign in
-
Interesting article on the threat to Big Pharma from tech-driven upstart rivals - Interesting read Big Pharma is under threat from tech-driven upstart rivals Big Pharma faces a growing threat from tech-driven rivals like Vertex Pharmaceuticals, Amgen, Regeneron, and Genmab, whose combined market value has surged by $270 billion over the past five years, while traditional giants like Pfizer, Novartis, and Roche have seen declines. These upstarts are leveraging technology to innovate and grow rapidly, challenging the dominance of century-old firms that built their power through strategic deals and a focus on common diseases. As competition intensifies and patent exclusivity wanes, traditional drugmakers face rising acquisition costs and fewer target options, potentially leading to a reversal of fortunes between established companies and emerging biotech challengers. https://lnkd.in/eKFg2hZi
Breakingviews - New Pharma will crowd out Big Pharma
reuters.com
To view or add a comment, sign in
-
FINGERPOST's recent webinar with Scientist.com on early market access for biotech and investors can be viewed in a short recap below. #marketaccess #pharma #biotech
Why does market access play such a critical role in drug development? In our recent discussion with FINGERPOST, industry experts share their perspectives on the importance of market access and health economics and outcomes research (HEOR) in early commercial decision-making for biotech and large pharmaceutical companies. Read the blog recap today: https://lnkd.in/gXXzRY7j Mel Walker, Joep Muijrers, Sandeep Duttagupta, Sahil Kirpekar, MD, Hilary Hutton-Squire
From Development to Delivery: Prioritizing Market Access in Biotech and Pharma
app.scientist.com
To view or add a comment, sign in
-
Why does market access play such a critical role in drug development? In our recent discussion with FINGERPOST, industry experts share their perspectives on the importance of market access and health economics and outcomes research (HEOR) in early commercial decision-making for biotech and large pharmaceutical companies. Read the blog recap today: https://lnkd.in/gXXzRY7j Mel Walker, Joep Muijrers, Sandeep Duttagupta, Sahil Kirpekar, MD, Hilary Hutton-Squire
From Development to Delivery: Prioritizing Market Access in Biotech and Pharma
app.scientist.com
To view or add a comment, sign in